AP3343A - Pyrazole compounds as CRTH2 antagonists - Google Patents

Pyrazole compounds as CRTH2 antagonists

Info

Publication number
AP3343A
AP3343A AP2013006942A AP2013006942A AP3343A AP 3343 A AP3343 A AP 3343A AP 2013006942 A AP2013006942 A AP 2013006942A AP 2013006942 A AP2013006942 A AP 2013006942A AP 3343 A AP3343 A AP 3343A
Authority
AP
ARIPO
Prior art keywords
pyrazole compounds
crth2 antagonists
crth2
antagonists
pyrazole
Prior art date
Application number
AP2013006942A
Other languages
English (en)
Other versions
AP2013006942A0 (en
Inventor
Thorsten Oost
Ralf Anderskewitz
Wolfgang Rist
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43799503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP3343(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AP2013006942A0 publication Critical patent/AP2013006942A0/xx
Application granted granted Critical
Publication of AP3343A publication Critical patent/AP3343A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AP2013006942A 2011-01-24 2012-01-20 Pyrazole compounds as CRTH2 antagonists AP3343A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11151876 2011-01-24
PCT/EP2012/050830 WO2012101043A1 (en) 2011-01-24 2012-01-20 Pyrazole compounds as crth2 antagonists

Publications (2)

Publication Number Publication Date
AP2013006942A0 AP2013006942A0 (en) 2013-06-30
AP3343A true AP3343A (en) 2015-07-31

Family

ID=43799503

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2013006942A AP3343A (en) 2011-01-24 2012-01-20 Pyrazole compounds as CRTH2 antagonists

Country Status (36)

Country Link
US (1) US8759386B2 (zh)
EP (1) EP2668181B1 (zh)
JP (1) JP5695216B2 (zh)
KR (2) KR101923365B1 (zh)
CN (4) CN103339125B (zh)
AP (1) AP3343A (zh)
AR (1) AR084916A1 (zh)
AU (1) AU2012210718B2 (zh)
BR (1) BR112013017570B1 (zh)
CA (1) CA2825458C (zh)
CL (1) CL2013001945A1 (zh)
CO (1) CO6801731A2 (zh)
CY (1) CY1116012T1 (zh)
DK (1) DK2668181T3 (zh)
EA (1) EA022559B1 (zh)
EC (1) ECSP13012832A (zh)
ES (1) ES2529452T3 (zh)
GE (1) GEP20156332B (zh)
HK (3) HK1186183A1 (zh)
HR (1) HRP20150069T1 (zh)
IL (1) IL226920A (zh)
MA (1) MA34838B1 (zh)
MX (1) MX342830B (zh)
MY (1) MY163012A (zh)
PE (1) PE20140860A1 (zh)
PH (1) PH12018501531A1 (zh)
PL (1) PL2668181T3 (zh)
PT (1) PT2668181E (zh)
RS (1) RS53785B1 (zh)
SG (1) SG192096A1 (zh)
SI (1) SI2668181T1 (zh)
TN (1) TN2013000280A1 (zh)
TW (1) TWI527809B (zh)
UA (1) UA109696C2 (zh)
UY (1) UY33873A (zh)
WO (1) WO2012101043A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI527809B (zh) * 2011-01-24 2016-04-01 百靈佳殷格翰國際股份有限公司 作為ｃｒｔｈ２拮抗劑之吡唑化合物
EP2688882B1 (en) * 2011-03-25 2015-05-13 Boehringer Ingelheim International GmbH Pyrazole compounds as crth2 antagonists
US20140148492A1 (en) * 2012-11-23 2014-05-29 Boehringer Ingelheim International Gmbh Bicyclosubstituted pyrazole compounds for treating hair loss
WO2014079805A1 (en) * 2012-11-23 2014-05-30 Boehringer Ingelheim International Gmbh Pyrazole compounds for treating hairloss
WO2019183472A1 (en) * 2018-03-23 2019-09-26 Palatin Technologies, Inc. Melanocortin receptor-specific peptide formulations and methods for gastrointestinal tract-specific delivery
WO2020132384A1 (en) 2018-12-21 2020-06-25 Celgene Corporation Thienopyridine inhibitors of ripk2

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010057118A2 (en) * 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Heterocyclic antagonists of prostaglandin d2 receptors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260322A (en) 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
PT1228067E (pt) * 1999-11-10 2004-11-30 Takeda Chemical Industries Ltd Compostos heterociclicos de cinco membros com actividade hipoglicemica e hipolipidemica
DK1471057T3 (da) 2003-04-25 2006-05-15 Actimis Pharmaceuticals Inc Pyrimidinyleddikesyrederivater, der er egnede til behandlingen af sygdomme medieret af CRTH2
JP2007509104A (ja) 2003-10-24 2007-04-12 グラクソ　グループ　リミテッド 複素環式化合物
CN101084209A (zh) * 2004-12-21 2007-12-05 德福根有限公司 具有Kv4离子通道活性的化合物
JP4950542B2 (ja) * 2006-04-07 2012-06-13 岩手東芝エレクトロニクス株式会社 固体撮像装置およびその製造方法
ATE489088T1 (de) 2006-06-06 2010-12-15 Glaxo Group Ltd N- (phenylmethyl) -2- (1h-pyrazol-4-yl) acetamid- derivate als p2x7-antagonisten zur behandlung von schmerzen, entzündungen und neurodegeneration
KR20090074264A (ko) * 2006-11-27 2009-07-06 화이자 프로덕츠 인코포레이티드 피라졸 유사체
EP2205569B1 (en) 2007-09-25 2012-02-29 Actimis Pharmaceuticals, Inc., Alkylthio pyrimidines as crth2 antagonists
JP5600594B2 (ja) * 2007-09-25 2014-10-01 アクチミス ファーマシューティカルズ インコーポレーテッド Ｃｒｔｈ２アンタゴニストとしての２−ｓ−ベンジル置換ピリミジン
JP2011088826A (ja) * 2008-01-31 2011-05-06 Astellas Pharma Inc 芳香族カルボン酸化合物
AU2009266793B2 (en) * 2008-07-03 2012-12-20 Brickell Biotech, Inc. Antagonists of prostaglandin D2 receptors
GB2463788B (en) * 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
JP2012517405A (ja) * 2009-02-09 2012-08-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器及び胃腸の疾患の治療のための新規医薬組成物
KR101906791B1 (ko) * 2010-01-27 2018-10-11 베링거 인겔하임 인터내셔날 게엠베하 Ｃｒｔｈ２ 길항제로서의 피라졸 화합물
EP2598145A1 (en) * 2010-07-28 2013-06-05 Boehringer Ingelheim International GmbH Pharmaceutical composition for treatment of respiratory and inflammatory diseases
TWI527809B (zh) * 2011-01-24 2016-04-01 百靈佳殷格翰國際股份有限公司 作為ｃｒｔｈ２拮抗劑之吡唑化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010057118A2 (en) * 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Heterocyclic antagonists of prostaglandin d2 receptors

Also Published As

Publication number Publication date
SG192096A1 (en) 2013-08-30
DK2668181T3 (da) 2015-01-19
UA109696C2 (xx) 2015-09-25
HK1210467A1 (zh) 2016-04-22
CY1116012T1 (el) 2017-01-25
TN2013000280A1 (en) 2014-11-10
PT2668181E (pt) 2015-02-05
RS53785B1 (en) 2015-06-30
PH12018501531A1 (en) 2019-04-08
TW201245184A (en) 2012-11-16
CA2825458C (en) 2021-01-26
BR112013017570A2 (pt) 2016-10-18
ES2529452T3 (es) 2015-02-20
CN104628705B (zh) 2017-04-12
CA2825458A1 (en) 2012-08-02
AU2012210718B2 (en) 2016-06-02
BR112013017570B1 (pt) 2022-01-11
KR101923365B1 (ko) 2018-11-30
JP2014502986A (ja) 2014-02-06
NZ611695A (en) 2015-04-24
EA022559B1 (ru) 2016-01-29
EP2668181A1 (en) 2013-12-04
HK1186183A1 (zh) 2014-03-07
SI2668181T1 (sl) 2015-02-27
UY33873A (es) 2012-07-31
GEP20156332B (en) 2015-07-27
MX2013008082A (es) 2013-09-13
KR102251939B1 (ko) 2021-05-14
CN107011332B (zh) 2020-03-13
HRP20150069T1 (hr) 2015-02-27
PE20140860A1 (es) 2014-07-20
CN104628705A (zh) 2015-05-20
MA34838B1 (fr) 2014-01-02
ECSP13012832A (es) 2013-09-30
MY163012A (en) 2017-07-31
US8759386B2 (en) 2014-06-24
CN103339125B (zh) 2015-07-15
AR084916A1 (es) 2013-07-10
IL226920A (en) 2016-11-30
PL2668181T3 (pl) 2015-04-30
CN104961732B (zh) 2017-07-11
US20130023576A1 (en) 2013-01-24
HK1215247A1 (zh) 2016-08-19
WO2012101043A1 (en) 2012-08-02
MX342830B (es) 2016-10-14
KR20140005931A (ko) 2014-01-15
CN107011332A (zh) 2017-08-04
CL2013001945A1 (es) 2013-10-25
CO6801731A2 (es) 2013-11-29
EP2668181B1 (en) 2014-11-05
EA201300857A1 (ru) 2013-12-30
AP2013006942A0 (en) 2013-06-30
JP5695216B2 (ja) 2015-04-01
TWI527809B (zh) 2016-04-01
CN103339125A (zh) 2013-10-02
CN104961732A (zh) 2015-10-07
AU2012210718A1 (en) 2013-07-04
KR20180129962A (ko) 2018-12-05

Similar Documents

Publication Publication Date Title
IL286152A (en) Modified imidazopyridinyl-aminopyridine compounds
AP3360A (en) Pyrazole compounds as CRTH2 antagonists
EP2627178A4 (en) QUINAZOLINONE-LIKE COMPOUNDS AS CRTH2 ANTAGONISTS
AP3391A (en) 2-Amino-4-arylthiazole compounds as TROA1 antagonists
EP2698368A4 (en) NEW PYRAZOLE DERIVATIVE
EP2738170A4 (en) HETEROCYCLIC COMPOUND
GB201118652D0 (en) New compounds
GB201118654D0 (en) New compounds
GB201118675D0 (en) New compounds
EP2709609A4 (en) HETEROCYCLIC COMPOUNDS
HK1191862A1 (zh) 吡唑衍生物
GB201106814D0 (en) New compounds
HK1210467A1 (zh) 作為 拮抗劑的吡唑化合物
EP2771012A4 (en) NEW CONNECTIONS
ZA201303800B (en) Pyrazole compounds
HK1191946A1 (zh) 新型六氫吡咯並咪唑酮化合物
GB201119590D0 (en) New compounds I
GB201102024D0 (en) Novel heterocyclic compounds 3
GB201101821D0 (en) Novel heterocyclic compounds 1
GB201101823D0 (en) Novel heterocyclic compounds 4
GB201101822D0 (en) Novel heterocyclic compounds 2